JP2022162047A5 - - Google Patents

Download PDF

Info

Publication number
JP2022162047A5
JP2022162047A5 JP2022132891A JP2022132891A JP2022162047A5 JP 2022162047 A5 JP2022162047 A5 JP 2022162047A5 JP 2022132891 A JP2022132891 A JP 2022132891A JP 2022132891 A JP2022132891 A JP 2022132891A JP 2022162047 A5 JP2022162047 A5 JP 2022162047A5
Authority
JP
Japan
Prior art keywords
hla
cell
cells
chain
hla class
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022132891A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022162047A (ja
JP7531925B2 (ja
Filing date
Publication date
Priority claimed from JP2019019289A external-priority patent/JP7130571B2/ja
Application filed filed Critical
Publication of JP2022162047A publication Critical patent/JP2022162047A/ja
Publication of JP2022162047A5 publication Critical patent/JP2022162047A5/ja
Priority to JP2024118377A priority Critical patent/JP2024144548A/ja
Application granted granted Critical
Publication of JP7531925B2 publication Critical patent/JP7531925B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022132891A 2012-04-17 2022-08-24 Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用 Active JP7531925B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024118377A JP2024144548A (ja) 2012-04-17 2024-07-24 Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261625314P 2012-04-17 2012-04-17
US61/625,314 2012-04-17
JP2019019289A JP7130571B2 (ja) 2012-04-17 2019-02-06 Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019019289A Division JP7130571B2 (ja) 2012-04-17 2019-02-06 Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024118377A Division JP2024144548A (ja) 2012-04-17 2024-07-24 Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用

Publications (3)

Publication Number Publication Date
JP2022162047A JP2022162047A (ja) 2022-10-21
JP2022162047A5 true JP2022162047A5 (enExample) 2023-07-03
JP7531925B2 JP7531925B2 (ja) 2024-08-13

Family

ID=48045753

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015507006A Pending JP2015514421A (ja) 2012-04-17 2013-03-15 Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用
JP2019019289A Active JP7130571B2 (ja) 2012-04-17 2019-02-06 Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用
JP2022132891A Active JP7531925B2 (ja) 2012-04-17 2022-08-24 Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用
JP2024118377A Pending JP2024144548A (ja) 2012-04-17 2024-07-24 Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2015507006A Pending JP2015514421A (ja) 2012-04-17 2013-03-15 Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用
JP2019019289A Active JP7130571B2 (ja) 2012-04-17 2019-02-06 Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024118377A Pending JP2024144548A (ja) 2012-04-17 2024-07-24 Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用

Country Status (12)

Country Link
US (2) US20150056225A1 (enExample)
EP (2) EP2838548B1 (enExample)
JP (4) JP2015514421A (enExample)
AU (1) AU2013249820C1 (enExample)
CA (2) CA3085032A1 (enExample)
DK (1) DK2838548T5 (enExample)
ES (1) ES2959382T3 (enExample)
FI (1) FI2838548T3 (enExample)
HU (1) HUE063231T2 (enExample)
PL (1) PL2838548T3 (enExample)
PT (1) PT2838548T (enExample)
WO (1) WO2013158292A1 (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX373460B (es) * 2014-03-11 2020-04-07 Cellectis Metodo para generar celulas t compatibles para el trasplante alogenico.
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
KR20170075013A (ko) * 2014-10-31 2017-06-30 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Cart 세포에서 유전자 발현의 변경 및 그의 용도
EP3215623A4 (en) * 2014-11-06 2018-09-26 President and Fellows of Harvard College Cells lacking b2m surface expression and methods for allogeneic administration of such cells
EP3229586B1 (en) 2014-12-10 2025-07-30 Regents of the University of Minnesota Genetically modified cells, tissues, and organs for treating disease
WO2016112779A1 (en) * 2015-01-17 2016-07-21 Zhejiang University Modified cells evoking reduced immunogenic responses
WO2016123100A1 (en) 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
CA2988854A1 (en) * 2015-05-08 2016-11-17 President And Fellows Of Harvard College Universal donor stem cells and related methods
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
EP4378957A3 (en) 2015-07-29 2024-08-07 Novartis AG Combination therapies comprising antibody molecules to pd-1
CN108368520B (zh) 2015-11-04 2023-01-17 菲特治疗公司 多能细胞的基因组工程改造
WO2017078807A1 (en) 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
EP3389712B1 (en) 2015-12-17 2024-04-10 Novartis AG Antibody molecules to pd-1 and uses thereof
HK1257518A1 (zh) 2016-01-11 2019-10-25 Novartis Ag 针对人白介素-2的免疫刺激性人源化单克隆抗体及其融合蛋白
CA3022227A1 (en) * 2016-04-27 2017-11-02 University Health Network (Uhn) Peptide-hla complexes and methods of producing same
KR20190103373A (ko) * 2017-01-13 2019-09-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 면역조작된 만능 세포
CN110637083A (zh) * 2017-03-20 2019-12-31 华盛顿大学 细胞及其使用和制备方法
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
US11312783B2 (en) 2017-06-22 2022-04-26 Novartis Ag Antibody molecules to CD73 and uses thereof
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
CA3067914A1 (en) 2017-06-30 2019-01-03 Cellectis Cellular immunotherapy for repetitive administration
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
WO2019129850A1 (en) 2017-12-29 2019-07-04 Cellectis Off-the-shelf engineered cells for therapy
JP7372920B2 (ja) 2017-12-29 2023-11-01 セレクティス Ｃａｒ ｔ細胞の作製を改良するための方法
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
CN112955542A (zh) * 2018-07-13 2021-06-11 L·杰罗姆罗 非免疫原性工程化组织及其生产方法和用途
US20210322473A1 (en) * 2018-07-18 2021-10-21 The General Hospital Corporation Modified t cells and methods of their use
CN110819592A (zh) * 2018-08-13 2020-02-21 赛元生物科技(杭州)有限公司 一种通用供体干细胞及其制备方法
SG11202108346WA (en) 2019-02-13 2021-08-30 Beam Therapeutics Inc Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
CA3138597A1 (en) 2019-05-10 2020-11-19 The Regents Of The University Of California Modified pluripotent cells
CN115279398B (zh) 2019-09-27 2025-07-04 比姆医疗股份有限公司 治疗液态癌症的组合物和方法
CA3170361A1 (en) * 2020-02-07 2021-08-12 Juntendo Educational Foundation Cytotoxic t cells derived from human t cell-derived ips cells
WO2021231712A1 (en) * 2020-05-15 2021-11-18 Rxcell Inc. Hypoimmunogenic cells and uses thereof in immune responses
WO2022038411A1 (en) 2020-08-19 2022-02-24 Astellas Pharma, Inc. Human non-naturally occurring modified fc region of igg specifically binding to non-naturally occurring modified fc receptor
EP4200023A4 (en) 2020-08-23 2024-10-30 Applied StemCell, Inc. Hla-f-modified cells and methods
CN114350612A (zh) * 2020-09-28 2022-04-15 未来智人再生医学研究院(广州)有限公司 表达靶向CTLA-4的shRNA/shRNA-miR的多能干细胞或其衍生物
CN114276995A (zh) * 2020-09-28 2022-04-05 未来智人再生医学研究院(广州)有限公司 一种表达ctla-4阻遏分子的多能干细胞及其衍生物
CN114457022A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达ox40激活型抗体的多能干细胞及其衍生物与应用
CN114517184A (zh) * 2020-10-30 2022-05-20 未来智人再生医学研究院(广州)有限公司 一种表达adipsin的多能干细胞或其衍生物及应用
CN114457021A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达cd47抗体的多能干细胞及其衍生物与应用
CN114525254A (zh) * 2020-10-30 2022-05-24 未来智人再生医学研究院(广州)有限公司 一种表达fgf-21的多能干细胞或其衍生物及应用
CN114457033A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达il-6阻断物的多能干细胞衍生物及其应用
CN114525257A (zh) * 2020-10-30 2022-05-24 未来智人再生医学研究院(广州)有限公司 一种表达Tim-3阻断物的多能干细胞或其衍生物及应用
CN114457030A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达IgE阻断物的多能干细胞或其衍生物及应用
CN114457024A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达IL-4Rα阻断物的多能干细胞或其衍生物及应用
CN114457026A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达4-1bb激活型抗体的多能干细胞及其衍生物与应用
CN114457028A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达cd38抗体的多能干细胞及其衍生物与应用
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
TW202237827A (zh) 2020-12-03 2022-10-01 美商世紀治療股份有限公司 經基因工程改造之細胞及其用途
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
CN114645021A (zh) * 2020-12-21 2022-06-21 未来智人再生医学研究院(广州)有限公司 一种表达靶向cd47抑制因子的多能干细胞及其衍生物与应用
CN114657131A (zh) * 2020-12-22 2022-06-24 未来智人再生医学研究院(广州)有限公司 一种表达尿酸氧化酶的多能干细胞或其衍生物
CN114657130A (zh) * 2020-12-22 2022-06-24 未来智人再生医学研究院(广州)有限公司 一种表达vegf-a靶向抑制因子的多能干细胞及其衍生物与应用
CN114657138A (zh) * 2020-12-22 2022-06-24 未来智人再生医学研究院(广州)有限公司 一种表达靶向B7-H4的shRNA和/或shRNA-miR的多能干细胞或其衍生物
CN114717192A (zh) * 2020-12-22 2022-07-08 未来智人再生医学研究院(广州)有限公司 一种表达Amyloidβ靶向抑制因子的多能干细胞及其衍生物与应用
CN114717193A (zh) * 2020-12-22 2022-07-08 未来智人再生医学研究院(广州)有限公司 一种表达靶向B7-H5的shRNA和/或shRNA-miR的多能干细胞或其衍生物
US11473060B2 (en) 2020-12-30 2022-10-18 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into NK cells
WO2022191216A1 (ja) 2021-03-09 2022-09-15 国立研究開発法人理化学研究所 低免疫原性網膜色素上皮細胞の製造方法
CA3216719A1 (en) 2021-05-03 2022-11-10 Astellas Institute For Regenerative Medicine Methods of generating mature corneal endothelial cells
TW202309268A (zh) 2021-05-07 2023-03-01 安斯泰來再生醫藥協會 產生成熟肝細胞的方法
AU2022299551A1 (en) * 2021-06-23 2024-01-18 Editas Medicine, Inc. Engineered cells for therapy
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer
US20260002124A1 (en) 2022-07-01 2026-01-01 Novo Nordisk A/S Enhancing neuronal differentiation of ventral midbrain neural progenitor cells
TW202417614A (zh) 2022-08-23 2024-05-01 安斯泰來再生醫藥協會 用於治療眼部病症的感光救援細胞（prc）組成物及方法
CN118207165B (zh) * 2022-12-07 2026-03-20 士泽生物医药（苏州）有限公司 一种表达stc1的通用型细胞及其制备方法
EP4735585A1 (en) 2023-06-30 2026-05-06 Novo Nordisk A/S Enhancing neuronal differentiation of neural progenitor cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5574205A (en) * 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
WO1991010470A1 (en) 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
WO1992009688A1 (en) * 1990-11-21 1992-06-11 Massachusetts Institute Of Technology MICE HAVING β2 MICROGLOBULIN GENE DISRUPTION
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
US5869270A (en) * 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
EP0995798A1 (en) * 1998-10-24 2000-04-26 Novimmune Sa Transcription factor of MHC class II genes, substances capable of inhibiting this new transcription factor and medical uses of these substances
US20040225112A1 (en) 2003-05-06 2004-11-11 Crew Mark D. Genes encoding single chain human leukocyte antigen E (HLA-E) proteins to prevent natural killer cell-mediated cytotoxicity
WO2007091078A2 (en) 2006-02-10 2007-08-16 Axordia Limited Polypeptide conjugate comprising hla-g and uses thereof, stem cells transfected with hla-g
US8105831B2 (en) 2007-03-09 2012-01-31 University Of Washington Parvoviral production of HLA homozygous cells
CA3157027A1 (en) * 2010-07-21 2012-01-26 Sangamo Therapeutics, Inc. Methods and compositions for modification of a t-cell receptor gene
JP2014513948A (ja) * 2011-04-20 2014-06-19 ザ ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャライゼーション β２ミクログロブリン欠損細胞

Similar Documents

Publication Publication Date Title
JP2024144548A5 (enExample)
JP7531925B2 (ja) Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用
JP2023073426A (ja) β２ミクログロブリン欠損細胞
JP2025010296A5 (enExample)
JP2022547053A5 (enExample)
JP2018174946A5 (enExample)
EP0879282A1 (en) Immunotherapy using cytotoxic t lymphocytes (ctl)
Partanen et al. Low degree of DNA polymorphism in the HLA‐linked lymphotoxin (tumour necrosis factor β) gene
CA2566903A1 (en) Modified antigen-presenting cells
US12492237B2 (en) T cell receptors targeting PIK3CA mutations and uses thereof
US20240285737A1 (en) Improved methods of treatment using immunogenic peptides
JP2022553328A5 (enExample)
JP2023540888A5 (enExample)
Sullivan et al. Molecular analysis of the bare lymphocyte syndrome.
US20260139026A1 (en) T cell receptors targeting pik3ca mutations and uses thereof
Jacobson et al. Virus-specific HLA class II-restricted cytotoxic T cells
Voogd Exploring HLA-E restricted M cobacterium tuberculosis specific T cells as accination targets for Tuberculosis
AU767173B2 (en) Immunotherapy using cytotoxic T lymphocytes (CTL)
Perarnau et al. Histocompatibility Antigens
Ascher Gene therapy: Advances and limitations
Shiv Pillai Cancer Center, Massachusetts General Hospital and Harvard Medical School
Robert The major histocompatibility complex